Marginal Zone Lymphoma (MZL) Overview

Save information for later
Sign Up

Learn About Marginal Zone Lymphoma (MZL)

What is the definition of Marginal Zone Lymphoma (MZL)?
Marginal zone lymphoma refers to a group of slow-growing non-Hodgkin B-cell lymphomas. Marginal zone lymphomas form in the marginal zone of lymphatic tissues, which include the spleen, lymph nodes, and other lymphoid tissue that contains B cells. B cells are a type of white blood cell. There are three types of marginal zone lymphomas: 1) extranodal marginal zone lymphoma, which most often occurs in the stomach; 2) mucosa-associated lymphoid tissue lymphoma; and 3) splenic marginal zone lymphoma.
What are the symptoms of Marginal Zone Lymphoma (MZL)?
Some patients with marginal zone lymphoma may not have any symptoms. Symptoms of marginal zone lymphoma include widespread swollen lymph nodes, fatigue, unexplained weight loss, fever, night sweats, and anemia.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Marginal Zone Lymphoma (MZL)?
Treatment for marginal zone lymphoma is individualized, depending on the type. Some patients with marginal zone lymphoma may not require any treatment at first, just watchful waiting. Treatment for marginal zone lymphoma may include radiotherapy; rituximab; immunochemotherapy with rituximab plus chemotherapy, with or without an anthracycline, or bendamustine/chlorambucil; B cell receptor inhibitors, such as ibrutinib; immodulatory agents, such as lenalidomide; and phosphoinositide 3-kinase inhibitors, such as copanlisib and umbralisib.
Who are the top Marginal Zone Lymphoma (MZL) Local Doctors?
Elite in Marginal Zone Lymphoma (MZL)
Dr. Felipe Samaniego
Oncology
Elite in Marginal Zone Lymphoma (MZL)
Dr. Felipe Samaniego
Oncology
1515 Holcombe Blvd, 
Houston, TX 
713-792-6161
Languages Spoken:
English
See accepted insurances

Felipe Samaniego is an Oncologist in Houston, Texas. Dr. Samaniego and is rated as an Elite provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

David G. Oscier
Elite in Marginal Zone Lymphoma (MZL)
David G. Oscier
Elite in Marginal Zone Lymphoma (MZL)
David G. Oscier
Bournemouth, ENG, GB 

David Oscier practices in Bournemouth, United Kingdom. Mr. Oscier and is rated as an Elite expert by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Marginal Zone Lymphoma (MZL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Leukemia.

 
 
 
 
Learn about our expert tiers
Learn More
Estella Matutes
Elite in Marginal Zone Lymphoma (MZL)
Estella Matutes
Elite in Marginal Zone Lymphoma (MZL)
Estella Matutes
Barcelona, CT, ES 

Estella Matutes practices in Barcelona, Spain. Ms. Matutes and is rated as an Elite expert by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Marginal Zone Lymphoma (MZL), Splenic Neoplasm, Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), and Splenectomy.

View All Doctors
What are the latest Marginal Zone Lymphoma (MZL) Clinical Trials?
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Enrollment Status: Recruiting
Publish Date: June 17, 2025

Eligibility: * Diagnosis of CLL/SLL and on treatment/previously treated/nearing treatment * Diagnosis of LPL/WM * As of February 5, 2025, patients with MBL and SMZL will no longer be enrolled. * Age greater than or equal to 18 years. * ECOG performance status of 0-2. Design Patients are typically followed every 6 to 24 months in the clinic and have blood drawn. Patients may be asked to undergo additional testi...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Open-Label Phase II Clinical Study of Orelabrutinib Combined With Rituximab Versus R-CVP in the Treatment of Newly Diagnosed Marginal Zone Lymphoma (MZL).
A Randomized, Open-Label Phase II Clinical Study of Orelabrutinib Combined With Rituximab Versus R-CVP in the Treatment of Newly Diagnosed Marginal Zone Lymphoma (MZL).
Enrollment Status: Recruiting
Publish Date: June 17, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is a randomized, open-label, multicenter, prospective clinical trial aimed at evaluating the efficacy and safety of orelabrutinib combined with rituximab for the previously untreat MZL

View All Clinical Trials